IL162747A0 - Modulation of heat-shock-protein-based immunotherapies - Google Patents
Modulation of heat-shock-protein-based immunotherapiesInfo
- Publication number
- IL162747A0 IL162747A0 IL16274702A IL16274702A IL162747A0 IL 162747 A0 IL162747 A0 IL 162747A0 IL 16274702 A IL16274702 A IL 16274702A IL 16274702 A IL16274702 A IL 16274702A IL 162747 A0 IL162747 A0 IL 162747A0
- Authority
- IL
- Israel
- Prior art keywords
- shock
- modulation
- protein
- heat
- based immunotherapies
- Prior art date
Links
- 102000002812 Heat-Shock Proteins Human genes 0.000 title 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
- A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
- A61K49/0043—Fluorescein, used in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0045—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent agent being a peptide or protein used for imaging or diagnosis in vivo
- A61K49/0047—Green fluorescent protein [GFP]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6043—Heat shock proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nanotechnology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Radiology & Medical Imaging (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34257001P | 2001-12-26 | 2001-12-26 | |
US34388401P | 2001-12-27 | 2001-12-27 | |
US37262002P | 2002-04-12 | 2002-04-12 | |
US39934202P | 2002-07-29 | 2002-07-29 | |
US41483402P | 2002-09-28 | 2002-09-28 | |
PCT/US2002/041373 WO2003062262A2 (en) | 2001-12-26 | 2002-12-24 | Modulation of heat-shock-protein-based immunotherapies |
Publications (1)
Publication Number | Publication Date |
---|---|
IL162747A0 true IL162747A0 (en) | 2005-11-20 |
Family
ID=27617918
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16274702A IL162747A0 (en) | 2001-12-26 | 2002-12-24 | Modulation of heat-shock-protein-based immunotherapies |
Country Status (5)
Country | Link |
---|---|
US (1) | US20040071656A1 (xx) |
EP (1) | EP1501860A4 (xx) |
JP (1) | JP2005514941A (xx) |
IL (1) | IL162747A0 (xx) |
WO (1) | WO2003062262A2 (xx) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7420037B2 (en) * | 2003-02-13 | 2008-09-02 | Antigenics Inc. | Heat shock protein-based vaccines and immunotherapies |
US7309491B2 (en) * | 2003-04-11 | 2007-12-18 | Antigenics Inc. | Heat shock protein-based vaccines and immunotherapies |
AU2004229458B2 (en) * | 2003-04-11 | 2009-11-19 | Antigenics, Inc. | Improved heat shock protein-based vaccines and immunotherapies |
US7575738B2 (en) * | 2004-08-13 | 2009-08-18 | General Electric Company | Heat shock protein as a targeting agent for endothelium-specific in vivo transduction |
US20140255449A1 (en) * | 2011-07-21 | 2014-09-11 | Biotech Tools S.A. | Dosage of dnak |
CN104254339B (zh) * | 2012-04-16 | 2020-01-21 | 路博润高级材料公司 | 用于治疗和/或护理皮肤和/或粘膜的化合物和它们在化妆品组合物或药物组合物中的用途 |
SG10201912485PA (en) * | 2015-05-13 | 2020-02-27 | Agenus Inc | Vaccines for treatment and prevention of cancer |
AU2018314269B2 (en) * | 2017-08-11 | 2022-12-08 | University Of Kentucky Research Foundation | Anti-neurodegenerative therapeutic, method of manufacture, and use |
CN112218883A (zh) | 2018-04-26 | 2021-01-12 | 艾吉纳斯公司 | 热休克蛋白结合肽组合物及其使用方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5750119A (en) * | 1994-01-13 | 1998-05-12 | Mount Sinai School Of Medicine Of The City University Of New York | Immunotherapeutic stress protein-peptide complexes against cancer |
EP1067194A1 (en) * | 1999-04-16 | 2001-01-10 | F. Hoffmann-La Roche Ag | Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof |
US20020086276A1 (en) * | 2000-12-28 | 2002-07-04 | Srivastava Pramod K. | Immunotherapeutic methods for extracorporeal modulation of CD36 and its ligands |
-
2002
- 2002-12-23 US US10/328,953 patent/US20040071656A1/en not_active Abandoned
- 2002-12-24 WO PCT/US2002/041373 patent/WO2003062262A2/en active Search and Examination
- 2002-12-24 IL IL16274702A patent/IL162747A0/xx unknown
- 2002-12-24 EP EP02806627A patent/EP1501860A4/en not_active Withdrawn
- 2002-12-24 JP JP2003562139A patent/JP2005514941A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2005514941A (ja) | 2005-05-26 |
WO2003062262A3 (en) | 2004-12-09 |
WO2003062262A2 (en) | 2003-07-31 |
US20040071656A1 (en) | 2004-04-15 |
EP1501860A2 (en) | 2005-02-02 |
EP1501860A4 (en) | 2006-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW487177U (en) | Anti-dust lid of connecting slot | |
HK1208446A1 (en) | Derivatives of uk-2a uk-2a | |
HK1067907A1 (en) | Amplifier modulation | |
AU148109S (en) | Lid | |
AU148235S (en) | Lid | |
AU2003252072A8 (en) | Modulation of protein kinase c-iota expression | |
EP1420651A4 (en) | PRESERVATION OF AGRICULTURAL PRODUCTS | |
HK1049618A1 (zh) | 骨質形成調節 | |
AU2002366788A8 (en) | Antisense modulation of ship-1 expression | |
EP1429782A4 (en) | MODULATION OF VITAMIN STORAGE | |
AU2002318139A1 (en) | Antisense modulation of src-c expression | |
IL162747A0 (en) | Modulation of heat-shock-protein-based immunotherapies | |
GB0124321D0 (en) | Modulation determination | |
GB0126781D0 (en) | Modulation | |
AU2002357102A8 (en) | Antisense modulation of cd36l1 expression | |
HUP0500734A3 (en) | Use of 2-alkoxyphenyl-substituted imidazotriazinones | |
AU2003297897A8 (en) | Modulation of stat 6 expression | |
AU2003295790A8 (en) | Modulation of iap-like expression | |
IL161178A0 (en) | MODIFICATIONS OF SOLID 3-sn-PHOSPHOGLYCERIDES | |
AU149667S (en) | Lid | |
AU2002347809A1 (en) | Antisense modulation of inhibitor-kappa b kinase-gamma expression | |
AU2003295794A8 (en) | Modulation of stat2 expression | |
AU2003241496A8 (en) | Antisense modulation of inhibitor-kappa b kinase-beta expression | |
AU2002329838A1 (en) | Modulation of appl expression | |
GB2377126B (en) | Frequency difference reduction |